Tag: Abivax
Abivax includes the first patient in the United States in its global phase 3 program with obefazimod in ulcerative colitis. – 10/11/2022 at 6:06 p.m.
ABIVAX press release Abivax includes the first patient in the United States in its global phase 3 program with obefazimod in ulcerative colitis. First patient included in the United States…
Abivax: 1st patient included in a phase 3 study in the USA – 10/11/2022 at 6:15 pm
(CercleFinance.com) – Abivax announces that it has enrolled the first patient in the United States in its global phase 3 program (ABTECT) for the drug candidate obefazimod in the treatment…
Abivax includes a first patient in its phase 3 program with obefazimod (rectocolitis) – 10/11/2022 at 18:17
(AOF) – The clinical phase 3 biotechnology company Abivax announces that it has enrolled the first patient in the United States in its global phase 3 program with Obefazimod in…
Abivax: 1st patient included in a phase 3 study in the USA
(CercleFinance.com) – Abivax announces that it has enrolled the first patient in the United States in its global phase 3 program (ABTECT) for the drug candidate obefazimod in the treatment…
Abivax announces the holding of an ordinary and extraordinary ad hoc Meeting on November 9, 2022. – 03/10/2022 at 18:05
ABIVAX press release Abivax announces the holding of an ordinary and extraordinary ad hoc Meeting on November 9, 2022. Abivax SA, a clinical-stage Phase 3 biotechnology company developing novel immune-modulating…
Abivax: Abstract on phase 2b results of obefazimod selected for poster presentation at UEG Week 2022. – 09/27/2022 at 18:05
ABIVAX press release Abivax: Abstract of Obefazimod phase 2b results selected for poster presentation at UEG Week Congress 2022. Interim analysis on safety and efficacy after 48 weeks of treatment…
Abivax: at what price?
By Claude Leguilloux Published on 09/16/2022 at 3:51 p.m. Abivax fell by 1.2% to 8.78 euros on Friday, while the group’s operating profit stood…
Abivax presents its 2022 half-year results and provides a progress report on its activities. – 09/15/2022 at 6:05 p.m.
ABIVAX press release Abivax presents its 2022 half-year results and provides a progress report on its activities. The global pivotal Phase 3 program with obefazimod in ulcerative colitis (UC) is…
Abivax: Deep Track exceeds 5% of capital
(CercleFinance.com) – Deep Track Biotechnology Master Fund Ltd, acting on behalf of the funds it manages, declared to the AMF that it crossed upwards, on September 7, the threshold of…
Abnormal volumes in Paris today: Abivax, Atos
During this trading session on Friday September 2, 2022, abnormal trading volumes were detected on the French market. Today, it is the Abivax share that stands out, with trading up…
Abivax: Biotech Abivax reassures the market by securing crucial financing
(BFM Bourse) – The company announced on Friday a capital increase of 46 million euros, carried out with a premium of nearly 10% compared to the closing price the day…
Abivax: Completion of a €49 million financing
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…